Louise Cadzow

The USP1 Inhibitor KSQ-4279 Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Tumors

Louise Cadzow, Jehrod Brenneman, Erica R. Tobin et al. · Cancer Research · 2024 · 34 citations · Full text

Rational design of a SOCS1-edited tumor-infiltrating lymphocyte therapy using CRISPR/Cas9 screens

Michael R. Schlabach, Sharon Lin, Zachary R. Collester et al. · Journal of Clinical Investigation · 2023 · 30 citations · Full text

Cancer Immunosurveillance, Crispr/cas9 Screens, Comprehensive Crispr +15

Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers

Louise Cadzow, J. Brenneman, H. Liu et al. · European Journal of Cancer · 2020 · 22 citations

First-in-class Usp1 Inhibitor, Medicine, Immunology +10

First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.

Timothy A. Yap, Nehal J. Lakhani, Amita Patnaik et al. · Journal of Clinical Oncology · 2024 · 16 citations